Evidence map›Paper›PMID 40501396›Full record

ArticleHaematologica2025

First-in-human pharmacokinetic, safety, and preliminary efficacy studies of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A.

Feng Xue, Shuxia Guo, Ping Liu, Weizhi Chen, Yun Chen, Qing Wen, Haiying Hua, Yu Cao, Xianqi Feng, Jing Sun and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The therapeutic landscape of inherited bleeding disorders in China.Research and practice in thrombosis and haemostasis · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Feng XueState Key Laboratory of Experimental Hematology, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin.
Shuxia GuoDepartment of Hematology, Zhengzhou People's Hospital, Zhengzhou.
Ping LiuDepartment of Hematology, Zhengzhou People's Hospital, Zhengzhou.
Weizhi ChenDepartment of Hematology, People's Hospital of Rizhao, Rizhao.
Yun ChenDepartment of Hematology, Jinan Central Hospital, Jinan.
Qing WenDepartment of Hematology, Jinan Central Hospital, Jinan.
Haiying HuaDepartment of Hematology, Affiliated Hospital of Jiangnan University, Yangzhou.
Yu CaoDepartment of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao.
Xianqi FengDepartment of Clinical Pharmacy, Affiliated Hospital of Qingdao University, Qingdao.
Jing SunDepartment of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou.
Chongyuan XuDepartment of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou.
Renchi YangState Key Laboratory of Experimental Hematology, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin. rcyang@ihcams.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40501396
PMCPMC12580702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.